DOI: 10.36347/sjams.2022.v10i09.003

Pages: 1431-1436

Patients with anti-glomerular basement membrane (anti-GBM) disease have Type IV collagen antigens in their glomerular and alveolar basement membranes. GN or alveolar bleeding develops quickly. Genetically vulnerable people may be activated by environmental factors. There isn't enough evidence to indicate a causal relationship between SARS- cov-2 and COVID-19. One in ten crescentic kidney disease patients has anti-GBM sickness. Early identification of circulating antibodies, increased awareness of rare and challenging clinical manifestations, and immunosuppressive and plasma exchange therapy have improved patients' prognoses. Anti-GBM disease is rare, but new medications and treatments are coming.